Red blood cell lifespan in long-term hemodialysis patients treated with roxadustat or recombinant human erythropoietin.

Abstract

INTRODUCTION:

A significant decrease in red blood cell (RBC) survival has been observed in patients with renal failure, which is supposed to contribute to renal anemia. The aim of this observational study was to determine RBC survival in hemodialysis (HD) patients treated with roxadustat or recombinant human erythropoietin (rhuEPO) compared with healthy persons.

METHODS:

RBC lifespan was measured by Levitt's CO breath test with newly developed automatic instrument ELS Tester.

RESULTS:

A total of 102 patients receiving long-term HD from two independent dialysis centers enrolled in the study, of whom 62 were treated with rhuEPO and 40 were on roxadustat therapy. A total of 25 healthy participants were recruited to match HD participants according to age and sex. Median RBC survival times in rhuEPO, roxadustat, and control groups were 65.0 (25th-75th percentile, 49.5-77.3), 75.5 (25th-75th percentile, 57.3-99.3), and 108.0 (25th-75th percentile, 89.0-141.5) d, respectively. Patients treated with roxadustat had significantly longer RBC survival time than patients treated with rhuEPO (p < .05). In multivariate analysis of factors affecting RBC lifespan in the whole HD patients, anemia treatment drugs (rhuEPO/roxadustat) and levels of hemoglobin were the significantly independent factors. RBC survival was not found to correlate with either weekly rhuEPO dosage (r = -0.087, p = .500) or weekly roxadustat dosage (r = -0.267, p = .110) in our cohort.

CONCLUSIONS:

HD patients treated with roxadustat had significantly longer RBC survival time than patients treated with rhuEPO, large prospective studies with long-term follow-up are warranted to verify the results in future. Abbreviations RBC: red blood cell; HD: hemodialysis; rhu EPO: recombinant human erythropoietin; ESRD: end-stage renal disease; EPO: erythropoietin; ROS: reactive oxygen species; CKD: chronic kideny disease; ESAs: erythropoiesis-stimulating agents; HIF-PHD: hypoxia-inducible factor prolyl hydroxylase; CO: carbon monoxide; Hb: hemoglobin.

• Authors: Xiaowei Yang, Bing Zhao, Jing Wang, Lei Wang, Min Tao, Jing Lu, Jiangong Lin, Jing Sun, Rong Wang
• Journal: Renal failure (Ren Fail) Vol. 43 Issue 1 Pg. 1428-1436 (Dec 2021) ISSN: 1525-6049 [Electronic] England
• PMID: 34657570 (Publication Type: Comparative Study, Journal Article, Multicenter Study, Observational Study)

Chemical References

• Hemoglobins
• Isoquinolines
• Epoetin Alfa
• Glycine
• roxadustat

Topics

• Adult
• Anemia (drug therapy)
• Case-Control Studies
• Cross-Sectional Studies
• Epoetin Alfa (therapeutic use)
• Erythrocyte Aging
• Glycine (analogs & derivatives, therapeutic use)
• Hemoglobins (analysis)
• Humans
• Isoquinolines (therapeutic use)
• Linear Models
• Male
• Middle Aged
• Renal Dialysis
• Renal Insufficiency, Chronic (complications, therapy)
• Treatment Outcome